Fundsmith LLP increased its position in Johnson & Johnson (NYSE:JNJ) by 24.1% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,704,693 shares of the company’s stock after buying an additional 719,532 shares during the period. Johnson & Johnson comprises approximately 7.1% of Fundsmith LLP’s portfolio, making the stock its 5th largest position. Fundsmith LLP owned approximately 0.14% of Johnson & Johnson worth $449,379,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the company. Americafirst Capital Management LLC bought a new stake in shares of Johnson & Johnson during the second quarter worth $101,000. Tuttle Tactical Management LLC acquired a new position in Johnson & Johnson during the second quarter valued at $103,000. Lenox Wealth Management Inc. boosted its position in Johnson & Johnson by 24.3% in the second quarter. Lenox Wealth Management Inc. now owns 972 shares of the company’s stock valued at $118,000 after buying an additional 190 shares in the last quarter. Thomas J. Herzfeld Advisors Inc. boosted its position in Johnson & Johnson by 221.2% in the second quarter. Thomas J. Herzfeld Advisors Inc. now owns 1,002 shares of the company’s stock valued at $122,000 after buying an additional 690 shares in the last quarter. Finally, NCM Capital Management Group Inc. acquired a new position in Johnson & Johnson during the second quarter valued at $127,000. 65.35% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) opened at 118.61 on Monday. Johnson & Johnson has a one year low of $94.28 and a one year high of $126.07. The company has a market cap of $322.68 billion, a PE ratio of 20.82 and a beta of 0.75. The stock has a 50 day moving average price of $117.08 and a 200 day moving average price of $118.16.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 18th. The company reported $1.68 earnings per share for the quarter, beating the consensus estimate of $1.66 by $0.02. Johnson & Johnson had a net margin of 22.03% and a return on equity of 25.30%. The firm had revenue of $17.80 billion for the quarter, compared to analyst estimates of $17.71 billion. During the same quarter in the prior year, the business earned $1.49 earnings per share. The business’s quarterly revenue was up 4.2% compared to the same quarter last year. On average, equities analysts anticipate that Johnson & Johnson will post $6.72 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 6th. Stockholders of record on Tuesday, November 22nd will be issued a dividend of $0.80 per share. The ex-dividend date of this dividend is Friday, November 18th. This represents a $3.20 annualized dividend and a dividend yield of 2.70%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.29. Johnson & Johnson’s dividend payout ratio is currently 56.64%.

Several equities analysts recently weighed in on the company. RBC Capital Markets reissued an “outperform” rating and set a $133.00 price objective (up previously from $125.00) on shares of Johnson & Johnson in a research report on Wednesday, July 20th. Leerink Swann reissued an “outperform” rating and set a $140.00 price objective (up previously from $125.00) on shares of Johnson & Johnson in a research report on Wednesday, July 20th. BMO Capital Markets reissued an “outperform” rating and set a $132.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, July 20th. Royal Bank Of Canada boosted their price objective on Johnson & Johnson from $125.00 to $133.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 20th. Finally, Deutsche Bank AG restated a “hold” rating and set a $142.00 price target (up from $125.00) on shares of Johnson & Johnson in a research note on Thursday, July 21st. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have assigned a buy rating to the company’s stock. Johnson & Johnson has an average rating of “Hold” and an average target price of $120.79.

In related news, Director Charles Prince acquired 875 shares of the company’s stock in a transaction dated Friday, October 21st. The shares were purchased at an average price of $114.11 per share, for a total transaction of $99,846.25. Following the completion of the acquisition, the director now owns 26,520 shares of the company’s stock, valued at $3,026,197.20. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.11% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.